聚维酮碘对鼻咽部COVID-19病毒杀灭效果:开放标签随机临床试验方案结构化摘要
该方案计划在孟加拉国达卡医学院医院开展单中心、开放标签、7臂平行组随机临床试验,评估不同浓度聚维酮碘(PVP-I)鼻腔冲洗或喷雾对鼻咽部COVID-19病毒的杀灭效果。主要结局是干预后1至15分钟RT-PCR仍阳性的比例,次要结局为不良事件。计划随机189例RT-PCR确诊患者,每组27例。
要点
- 7臂设计比较0.4%、0.5%、0.6% PVP-I鼻腔冲洗与0.5%、0.6%鼻腔喷雾及蒸馏水对照。
- 主要结局为干预后1至15分钟RT-PCR仍阳性的比例。
- 纳入15-90岁、症状4天内且RT-PCR确诊的COVID-19患者。
核心结论
- 该方案旨在评估PVP-I清除鼻咽部COVID-19病毒的 efficacy 及其不良事件。
研究设计与样本
- 单中心、开放标签、7臂平行组随机临床试验,在孟加拉国达卡医学院医院开展。
- 计划随机189例RT-PCR确诊的COVID-19患者,每个试验臂27例。
- 采用Microsoft Excel随机数生成法,由不参与试验的统计师通过密封信封分配;参与者资格评估和知情同意后立即随机。
关键数值与推荐
- 纳入标准:RT-PCR确诊COVID-19,年龄15-90岁,症状持续4天内,知情同意并接受随机分组。
- 排除标准:对PVP-I水溶液或其辅料已知过敏、既往诊断甲状腺疾病、慢性肾衰竭eGFR分期≥3(MDRD)、急性肾衰竭KDIGO≥2期(肌酐≥基线2倍)、需有创或无创通气或计划6小时内通气、妊娠或哺乳期女性。
- 干预措施:Arm-1为0.4% PVP-I鼻腔冲洗,Arm-2为0.5% PVP-I鼻腔冲洗,Arm-3为0.6% PVP-I鼻腔冲洗,Arm-4为0.5% PVP-I鼻腔喷雾,Arm-5为0.6% PVP-I鼻腔喷雾,Arm-6为蒸馏水鼻腔冲洗,Arm-7为蒸馏水鼻腔喷雾。
- 主要结局:干预后1分钟至15分钟仍COVID-19阳性的病例比例;次要结局:干预后不良事件发生情况。
- 所有组均接受相同的支持性和常规护理。
临床怎么用
- 该试验结果可能为PVP-I鼻腔局部用药降低鼻咽部病毒载量提供证据,但当前仅为方案摘要,尚不能指导临床实践。
局限性
- 开放标签设计,未设盲法或掩蔽。
- 单中心研究,样本量189例,每个试验臂27例。
- 试验方案版本1.5(2020年9月10日),预计2021年2月28日完成数据分析和招募。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: General: To assess the virucidal efficacy of povidone iodine (PVP-I) on COVID-19 virus located in the nasopharynx Specific: i. To evaluate the efficacy of povidone iodine (PVP-I) to removeCOVID-19 virus located in the nasopharynx ii. To assess the adverse events of PVP-I TRIAL DESIGN: This is a single-center, open-label randomized clinical trial with a 7-arm parallel-group design. PARTICIPANTS: The study will be conducted at Dhaka Medical College Hospital, Dhaka, Bangladesh. INCLUSION CRITERIA: All RT-PCR-confirmed COVID-19 cases aged between 15-90 years with symptoms for the past 4 days will be screened. Those who give informed consent, are willing to participate, and accept being randomized to any assigned group will also be considered for final inclusion. EXCLUSION CRITERIA: Patients with known sensitivity to PVP-I aqueous antiseptic solution or any of its listed excipients or previously diagnosed thyroid disease or who had a history of chronic renal failure: stage ≥3 by estimated glomerular filtration rate (eGFR) Modification of Diet in Renal Disease (MDRD) or had acute renal failure (KDIGO ≥stage 2: creatinine ≥2 times from the baseline) or patients who required invasive or noninvasive ventilation or planned within the next 6 hours were considered for exclusion. Moreover, lactating or pregnant women will also be restricted to include here. INTERVENTION AND COMPARATOR: This RCT consist of seven arms: Arm-1 (intervention group): will receive povidone iodine (PVP-I) nasal irrigation (NI) at a concentration of 0.4% Arm-2 (intervention group): will receive PVP-I nasal irrigation at a concentration of 0.5% Arm-3 (intervention group): will receive PVP-I nasal irrigation at a concentration of 0.6%. Arm-4 (intervention group): will receive PVP-I nasal spray (NS) at a concentration of 0.5%. Arm-5 (intervention group): will receive PVP-I nasal spray at a concentration of 0.6%. Arm-6 (placebo comparator group): will receive distilled water through NI Arm-7 (Placebo comparator group): will receive distilled water through NS The intervention arms will be compared to the placebo comparator arms. Other supportive and routine care will be the same in both groups. MAIN OUTCOMES: The primary outcome is the proportion of cases that remain COVID-19 positive following the intervention. It will be assessed from 1 minutes to 15 minutes after the intervention. Any occurrence of adverse effects following the intervention will be documented as a secondary outcome. RANDOMIZATION: The assignment to the study (intervention) or control (comparator) group will be allocated in equal numbers through randomization using random number generation in Microsoft Excel by a statistician who is not involved in the trial. The allocation scheme will be made by an independent statistician using a sealed envelope. The participants will be allocated immediately after the eligibility assessment and consenting procedures. BLINDING (MASKING): This is an open-label clinical trial, and no blinding or masking will be performed. NUMBERS TO BE RANDOMIZED (SAMPLE SIZE): A total of 189 confirmed cases of COVID-19 will be randomized into seven groups. In each arm, a total of 27 participants will be recruited. TRIAL STATUS: The current trial protocol is Version 1.5 from September 10, 2020. Recruitment began September 30, 2020 and is anticipated to be completed, including data analysis by February 28, 2021. TRIAL REGISTRATION: The trial protocol has been registered in the ClinicalTrials.gov on September 16, 2020. NCT Identifier number: NCT04549376 . FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting the dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol.
引用
- Hasan MJ, Rumi SKNF, Banu SS, et al. Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: A structured summary of a study protocol for an open-label randomized clinical trial. Trials. 2021. PMID: 33397432. doi:10.1186/s13063-020-04963-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。